6 결과
FIELD OF THE INVENTION
The present invention relates to a method for treating cancer patients with severe renal impairment.
BACKGROUND OF THE INVENTION
Trifluridine (also known as: .alpha.,.alpha.,.alpha.-trifluorothymidine; hereinafter, also referred to as "FTD") exhibits an antitumor effect by DNA
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage application of PCT/JP2013/000117, filed Jan. 15, 2013, which claims priority from Japanese application JP 2012-013497, filed Jan. 25, 2012.
TECHNICAL FIELD
The present invention relates to a tumor diagnostic agent
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition and, more particularly, to a pharmaceutical composition suitable as a radiation-sensitizer in the form of injection solution.
BACKGROUND ART
In cancer radiotherapy, 2-nitroimidazole derivatives are known to be useful drugs
TABLE OF CONTENTS
1. Introduction
2. Background of the Invention
2.1. T Cell Growth Factors and Receptors
2.2. T Cell Surface Molecules
2.3. Soluble Immune Cell Surface Molecules
2.4. Hairy Cell Leukemia
3. Summary of the Invention
3.1. Definitions
4. Description of the Figures
5. Detailed
BACKGROUND OF THE INVENTION
Chronic renal disease is a world-wide problem. In the United States, there were over 400,000 patients enrolled in Medicare-funded end-stage renal disease programs at the end of 2002. It is projected that by 2010, more than 650,000 patients will be enrolled in such
BACKGROUND OF THE INVENTION
Chronic renal disease is a world-wide problem. In the United States, there were over 400,000 patients enrolled in Medicare-funded end-stage renal disease programs at the end of 2002. It is projected that by 2010, more than 650,000 patients will be enrolled in such